// SUPPLIER · WHARTON'S JELLY · MSC EXOSOME MATERIAL

The material speaks for itself. We just make sure the paperwork is there.

B&H Bio supplies umbilical-cord-derived MSC exosome material to qualified professionals. Every batch ships with an independent Eurofins Certificate of Analysis, a specification sheet, and full batch-level traceability. No claims, no theater — just documented material.

Batch Specification EUR-####-##
MaterialMSC Exosome
SourceWharton's Jelly
ProcessingNon-lyophilized
CleanroomISO-5
Donor Screening21 CFR 1271
SterilityUSP <71>
Endotoxin<5 EU/mL
TraceabilityBatch-level
COA IssuerEurofins (3rd party)

Regulatory notice: No exosome product is FDA-approved for therapeutic use in humans. Material is supplied for research, professional, and investigational use only. Practices rely on their own regulatory counsel.

Two materials. Both documented.

Matrix

Amniotic fluid-derived MSC exosome material. Unadulterated — no mixing, no dilution after procurement.

Exosomes~1 trillion
Growth factors234
Particle size50–100 nm
SourceFull-term C-section
FormatNon-lyophilized
Alocyte

Allogeneic umbilical cord blood plasma combined with mononuclear cells. Minimally manipulated.

Exosomes~4 trillion
Growth factors175
Stem cellsup to 100M
SourceCord blood (allogeneic)
FormatCryopreserved (DMSO)

Both product lines are characterized using human cytokine array analysis (RayBiotech AAH-CYT-5-8), mass spectrometry proteomics, and mixed lymphocyte reaction (MLR) assays. Donor screening follows FDA 21 CFR 1271. Sterility and endotoxin testing performed by VRL Eurofins per USP <71> and USP <85>.

// FACILITY

ISO-5 cleanroom. Every batch handled under controlled conditions.

What ships with every batch.

  • 01
    Third-party Eurofins Certificate of Analysis

    An independent COA from Eurofins — not an in-house report. Covers sterility (USP <71>), endotoxin (USP <85>), and identity.

  • 02
    Specification sheet

    Describes the current batch in detail: exosome count, growth factor panel, particle size, source, and processing parameters.

  • 03
    Batch-level traceability

    Documentation is tied to the specific batch you receive. Every vial traces back to a screened donor and a documented manufacturing run.

  • 04
    Donor screening records

    Full-term, live-birth donated tissue. Donor qualification per FDA 21 CFR 1271, including infectious disease testing (HIV, HBV, HCV, CMV, HTLV, syphilis, West Nile, Zika, SARS-CoV-2).

We don't ask you to trust us. We hand you the documentation and let you decide.

If a competitor can't produce an independent COA, batch traceability, and donor screening records for the exact batch they're shipping you — ask why.

Request current-batch documentation →

Three steps. No sales calls required.

01

Request the current-batch COA and spec sheet.

Tell us your name, professional role, and what you're evaluating. We send the documentation — not a pitch deck.

02

Review the documentation against your own requirements.

Exosome count, growth factor panel, sterility, endotoxin, donor screening. Take it to your team. Compare it to what you're using now.

03

Contact us with questions — or place an order.

If the material meets your standards, we'll discuss current inventory and logistics. If it doesn't, we'd rather you know that before you buy.

What we do. What we don't.

We do: Supply MSC exosome material. Provide independent documentation. Maintain batch traceability. Answer technical questions about specifications, sourcing, and inventory.

We don't: Provide medical, clinical, or legal advice. Advise on use, protocols, or outcomes. Make therapeutic, disease, efficacy, safety, dosing, or FDA-approval claims. Sell to patients.

Decisions about how research material is used rest entirely with the qualified professionals who order it. Practices rely on their own regulatory counsel.

Evaluate the material on your own terms.

Request the current-batch Eurofins COA and specification sheet.

Request documentation →